ASCCT / ESTIV webinars

ESTIV organizes free webinars on a monthly basis together with the American Society for Cellular and Computational Toxicology (ASCCT). These webinars cover a broad spectrum of topics relevant to the fields of in vitro and in silico toxicology. ESTIV members are welcome to propose topics and speakers at any time. All webinars are recorded, archived and available for ESTIV members.

Webinars – 2022

ESTIV and ASCCT Webinars are available for all to attend and watch at no cost.

January 21, 2022: Advances in Genotoxicity: Reconstructed Skin Comet and Micronucleus Assays

Friday, January 21, 2022
10:00-11:30 EST / 4:00-5:30 CET

Recording is available at:


Stefan Pfuhler, Procter and Gamble
Kerstin Reisinger, Henkel AG & Co. KGaA

The in vitro genotoxicity test battery has a high sensitivity for prediction of in vivo genotoxic/carcinogenic agents but tends to over-predict the genotoxicity hazard, resulting in misleading positive results. To address this, the Cosmetics Europe Genotoxicity Task Force has established two in vitro skin genotoxicity models as follow up assays to the in vitro test battery for substances with dermal exposure: the reconstructed skin (RS) Comet assay and the RS micronucleus (RSMN) test. Here, we report on the completed validation of these assays. Both assays exhibited good sensitivity and specificity: 77% and 88% for 3D Skin Comet (32 compounds) and 80% and 87% for the RSMN (47 compounds). A combination of these assays enables detection of DNA damage leading to all 3 types of genotoxic damage (mutation, clastogenicity and aneugenicity). By applying an endpoint-triggered strategy, the sensitivity increased to 89%. The high predictivity for the expected in vivo outcome observed for these higher tier in vitro assays supports their use as follow-up tests to the standard test battery. For topically applied chemicals, the RSMN assay is recommended for in vitro positive chemicals that showed a clastogenic or aneugenic MoA; whereas, substances triggering gene mutation should be followed-up with a RS Comet assay. This tiered strategy shows great promise as an in vitro-only approach for genotoxicity testing of dermally exposed substances and both assays were recently accepted into the OECD guideline development program.


Webinars – 2021

December 16, 2021 – Award Winners webinar: Development and Application of In Vitro Data

This popular award winners series highlights the science of speakers who have been recognized by ASCCT and ESTIV in 2021.

Thursday, December 16, 2021
10:00-11:30 EST / 4:00-5:30 CET

The recording is available here:

Presenter 1: Agnes Karmaus, Integrated Laboratory Systems/NICEATM
Title: Gaining Context for High-Throughput In Vitro Data: Annotation Approaches and Visualization Tools

Availability of in vitro high-throughput screening (HTS) assay data is facilitating the development of computational approaches for chemical hazard assessment. Linking HTS data to regulatory endpoints remains a challenge and requires detailed information about assays as well as an understanding of biological context. For example, data from the U.S. Environmental Protection Agency’s ToxCast HTS program are annotated by technology platform, assay design, and assay/gene target information, yet it remains a challenge to provide toxicological context for potential regulatory applications. Here we present a mapping approach for HTS assay endpoints that moves beyond technology-based assay annotations. Our mapping provides a robust assay grouping schema applicable beyond HTS datasets in a toxicological endpoint-based framework. This expert-led curation and annotation is available in the Integrated Chemical Environment (ICE). Annotations map assays to regulatory toxicological endpoints of interest through structured vocabularies allowing data to be searched, grouped, and visualized by regulatory endpoint. The annotations increase accessibility for those unfamiliar with individual assays by providing context for in vitro assays (and in vivo data or in silico predictions in ICE) to facilitate identification of data gaps, insight into mechanistic plausibility, and investigation into regulatory-relevant endpoints. Finally, we highlight that while single assay results are generally insufficient for regulatory application, this approach helps integrate results from multiple assays and provides data visualization to aid review of a chemical’s potential activity for selected regulatory endpoints. This project was funded with federal funds from the NIEHS, NIH under Contract No. HHSN273201500010C.

Presenter 2: Saskia Galanjuk, IUF-Duesseldorf
Title: The human induced pluripotent stem cell (hiPS) test as an alternative method for developmental toxicity testing

The evaluation of substances for their potency to induce embryotoxicity is controlled by safety regulations. Test guidelines for reproductive and developmental toxicity are relying mainly on animal studies which make up the majority of animal usage in regulatory toxicology. Therefore, there is an urgent need for alternative in vitro methods to follow the 3R principles. To improve human safety, cell models based on human cells are of great interest to overcome species differences. Human induced pluripotent stem cells (hiPSCs) are an ideal cell source as they largely recapitulate embryonic stem cells without bearing ethical concerns and they are able to differentiate into most cell types of the human body. Here, we set up and characterized an FBS-free hiPSC-based in vitro test method, called the human induced pluripotent stem cell test (hiPS Test), to evaluate the embryotoxic potential of substances. After 10 days in culture, hiPSCs develop into beating cardiomyocytes. As terminal endpoint evaluations, cell viability, qPCR analyses as well as contraction frequency and area of beating cardiomyocytes by video analyses are measured.


November 30, 2021 – How to Control and to Maintain the Quality of Cell Cultures

Presenter: Oliver Wehmeier, acCELLerate GmbH

November 30, 2021
10:00-11:00 AM EST / 16:00-17:00 CET

The recording is available here

Human or animal derived cell lines are major cornerstones for the development of alternative methods. An increasing number of animal tests can now be replaced by cell-based assay. The various validated methods provide a good predictivity and high precision, but the reliability of the assays very much depends on the quality of cell culture. Although considered as in vitro, cells are still living organisms.

There are many determinants which modulate the proper function of cells and have an impact on the outcome of an assay. To know what these determinants are and to understand how they can be controlled and standardized is the holy grail of cell culture. Ways to prevent microbial contamination, the importance of regular mycoplasma testing as well as the problem of cross contamination among cell lines will be discussed. Also, variances which are caused from the cells and the cultivation process itself will be addressed. The guidance for a Good Cell Culture Practice as the essential basis for running reliable and precise cell-based assays will be introduced.

October 21, 2021 – EU REACH Regulation, EU Cosmetic Regulation, and new animal tests on cosmetic ingredients

Thursday, October 21, 2021
11:00 AM ET – 12:00 PM ET / 17:00 – 18:00 CET

Costanza Rovida, PhD, CAAT-Europe/Konstanz University
Jean Knight, White Rabbit Beauty

The recording is available here

EU REACH Regulation, EU Cosmetic Regulation, and new animal tests on cosmetic ingredients

Presenters: Costanza Rovida, PhD, CAAT-Europe/Konstanz University and Jean Knight, White Rabbit Beauty

EU Regulations are legislative acts that are immediately implemented in all 27 member states of the European Union. REACH is the most important regulation in the chemical area, requiring  all manufacturers and importers of chemicals in quantities above 1 ton/year to register the substances. The registration includes a detailed risk assessment, often based on new animal testing. Cosmetic ingredients are chemical substances that need full REACH registration. In addition to that, cosmetic ingredients are governed by the EU’s Cosmetic Regulation, which is focused on the protection of consumers when using cosmetics. Since 2009 for some endpoints and 2013 as a general rule, the Cosmetic Regulation has banned new in vivo tests of both finished cosmetics and cosmetic ingredients. This important ban has caused consumers to believe that EU cosmetics are not tested on animals. In a recent study, we demonstrated that this is not fully true, as many cosmetic ingredients are being tested in vivo for REACH purposes (

During the presentation we will describe both regulations and we will guide participants through the database of the European Chemical Agency (ECHA) where all the studies performed for registering chemical substances are stored. We will also explain the conflict between the two regulations regarding the possibility to test cosmetic ingredients on animals, by presenting the results of our analysis. Among the in new in vivo tests performed on cosmetic ingredients, some were necessary for REACH compliance, but others should have been avoided. The future is not bright with many more new tests asked by the authority to the registrants.

September 10, 2021- Organs-on-Chips: New science and standards for implementation

Meike van der Zande, PhD, Wageningen Food Safety Research
Monica Piergiovanni, PhD, European Commission Joint Research Centre

The recording is available here

Organ-on-Chip models for bioavailability, biotransformation, and (sub)chronic toxicity studies

Presented by Meike vander Zande

Organ-on-Chip (OoC) systems are promising tools for improvement of current in vitro models. Microfluidic flow conditions allow for accurate control of the extracellular chemical and physical microenvironment in which cells are grown, thus better recapitulating the in vivo tissue environment. As such, these models may facilitate the replacement of animal models.

During this presentation, two types of organ-on-chip models will be discussed, namely; intestinal and liver OoC systems. The intestinal systems vary in complexity ranging from a model based on Caco-2 epithelial cells to a tri-culture model composed of Caco-2, HT29-MTX (Goblet) and hMVEC (endothelial) cells. The liver model is comprised of HepaRG cells.

The design and characterization of the models will be discussed, focusing on critical parameters that should be evaluated. Furthermore, the models will be discussed in relation to their performance for bioavailability, biotransformation, and (sub)chronic toxicity studies, showing their potential for future application in the fields of pharmacology and toxicology.

The many roles of standards for Organ on Chip

Presented by Monica Piergiovanni

Organ-on-Chip (OoC) refers to a group of innovative technologies able to maintain and monitor living engineered human or animal tissues in a controlled microenvironment. The purpose of OoCs is to mimic specific aspects of organ physiology and function, including interactions between different organs in the body.

Standards are commonly seen as a means to bring innovation to the market, strengthening the industry and contributing to the Single Market strategy that we have in place in Europe. Standard methods are also great tools to provide a basis for regulatory acceptance, facilitating the use of new technologies, as is the case for alternative to animal methods.

There is a clear consensus in the OoC community on the need for standardisation to advance the field, with several initiatives now in progress worldwide. Standardisation can play a key role in ensuring proper characterisation of individual devices, benchmarking against appropriate reference elements and aiding efficient communication among stakeholders. This was also the subject of the join workshop of the European Commission Joint Research Centre, (EC-JRC) together with the European Standardization authorities (CEN/CENELEC). The workshop had the goal to bridge the research and developers community with the standardisers and regulators and build a list of areas where standards would contribute to wider acceptance and use of OoC. Standards can tackle multiple aspects of the OoC, from assessment of technical performance to material characterisation, from reference compound to cell sources, from reporting to quality control.

July 21, 2021 – Bridging toxicology and research: COVID-19 initiatives

Wednesday, 21 July, 2021
10:00 – 11:30 EDT

Marco Travaglio, PhD student, MRC Toxicology Unit, School of Biological Sciences, University of Cambridge
Maria João Amorim, PhD, Instituto Gulbenkian de Ciência

The recording is available here 

Links between air pollution and COVID-19 in England 

Presented by: Marco Travaglio

In the UK, the coronavirus disease 19 (COVID-19) has caused over 120,000 deaths. However, uncertainty remains surrounding environmental risk factors for this disease. In our study, we show a clear link between air pollution and COVID-19 in England. We compared SARS-CoV-2 cases and deaths recorded in public databases to both regional and subregional air pollution data monitored at multiple sites across England. Our results show that the levels of multiple markers of poor air quality, including nitrogen oxides PM2.5, are associated with increased COVID-19 deaths in England, after adjusting for population density and other socio-economic factors. We expanded our analysis using individual-level data from the UK Biobank and showed that particulate matters contribute to increased infectivity. Our results link the levels of some air pollutants to COVID-19 cases and adverse outcomes. This study provides a useful framework to guide health policies in countries affected by this pandemic. This was the first study to combine a population- and individual-level approach to investigate the impact of air pollution on COVID-19 infectivity and mortality in England. Our research uniquely places the disease within the context of potentially modifiable risk factors, providing a useful framework for implementing air quality management programmes for disease prevention and control.

COVID-19 through Adverse Outcome Pathways (AOP): building networks to understand the disease

Presented by: Maria João Amorim

The coronavirus disease 2019 (COVID-19) is an ongoing global public health problem caused by the severe acute respiratory syndrome coronavirus–2 (SARS-CoV-2) pandemics. Scientists around the world are producing invaluable data at an unprecedent speed in a mobilized effort to provide answers about this emerging virus. This webinar explains how the CIAO project is modelling COVID-19 pathogenesis at several layers by exploiting the Adverse Outcome Pathway (AOP) framework ( CIAO relies on an interdisciplinary crowdsourcing effort, synergizing experts of many fields to translate complex biology into simplified knowledge. It uses the open access Wiki platform to build evidence about the biological mode of action of the virus with the goal of informing policy and healthcare decisions. The project counts with the action of more than 65 scientists from 40 organizations around the world, which is steered by the European Commission, the Physicians Committee for Responsible Medicine and the Humane Society International.

June 23, 2021 – Human Induced Pluropotent Stem Cells (hIPSC) in Toxicology

Tuesday, June 23, 2021
10:00 – 11:30 EST / 16:00 – 17:30 CET

The recording is available here

Catherine Verfaillie, Leuven University
Anne Marie Vinggard, National Food Institute, Technical University of Denmark

Abstracts: “Multicellular 3D liver models based on hiPSC-derived liver cells“
Presented by Catherine Verfaillie

To address how toxic insults affect hepatocytes as well as non-parenchymal cells, murine or rat models are often used. However, interspecies differences between humans and rodents do not always allow extrapolating findings in animal models to the human patient. Therefore, human hepatoma cell lines with or without stellate cell, monocyte, and/or endothelial cell lines can be used. In addition, and more relevant, primary human liver cells can be used. However, It has long been established that when cultured on stiff culture plates, primary human hepatocytes (PHHs) very quickly lose functionality. This is also the case for hepatic stellate cells (HSCs)  that become quickly activated, and liver sinusoidal endothelial cells (LSECs) that very quickly lose their typical sinusoidal endothelial characteristics. Especially for hepatocytes, numerous studies have demonstrated that this can at least in part be prevented when cells are cultured for instance in sandwich cultures, in spheroids or embedded in scaffolds. Although the latter best mimic human liver, the scarcity of human liver cells and high inter-donor variation  represent important drawbacks. With the advent of pluripotent stem cells (PSCs), it is now possible to create PSC-derived hepatocyte-, HSC-, EC- and macrophage (Mφ)-like cells.  As PSCs are an inexhaustible cell population, this approach overcomes the issues related to low cell numbers and inter-donor variability of primary samples. To create more complete liver models, co-cultures of PSC-hepatocyte-like cell (HLC) progeny with mesenchymal cells and human umbilical vein endothelial cells (HUVECs) have been created, and more recent studies created liver models by co-differentiation of PSCs to hepatocyte- and NPC-like cells directly in spheroids. An alternative is the assembly of pre-differentiated PSC-HLCs and -NPC-like cells into co-cultures. During this presentation, data will be presented from studies exploiting the latter concept to create in vitro liver models that are stable for several weeks, and can be used to test drug metabolisation, drug toxicity or induction of liver inflammation and fibrosis.

“Novel human pluripotent stem cell-based assays to predict developmental toxicity“
Presented by Anne Marie Vinggard

As women are exposed to a plethora of chemicals during pregnancy, it is important to evaluate their safety for the developing embryo. For this, human based models are needed for enabling reliable and large scale risk assessment1. Human induced pluripotent stem cells (hiPSC) are an excellent tool to model embryonic development as they can form embryoid bodies (EBs) that mirror the early embryo in many structural and functional aspects, and can undergo differentiation programs that reflect molecular mechanisms during embryonic development2. Here, we present our recently developed assays for predicting developmental toxicity using hiPSC.

We used three different hiPSC lines and differentiated the cells through EBs into cardiomyocytes. The cells were exposed to chemicals for the last six days of differentiation and the beating EBs analyzed on the last day4. In order to characterize our system and to study potential molecular mechanisms-of-action, we also investigated global and targeted gene expression levels and protein cardiac markers.  We were able to show that our system mimics the first three weeks of embryonic development by analyzing markers for respective developmental stages3. Furthermore, the assay was able to detect the strong developmental toxicant thalidomide as positive while the neurodevelopmental toxicant valproic acid was negative. Interestingly, we also identified the fungicide epoxiconazole as a potentially hazardous chemical4 and studied the underlying mechanism-of-action. Moreover, we have created a human NKX2.5 reporter stem cell line for developmental toxicity testing with a greater sensitivity and a higher throughput5. In conclusion, we have developed two assays based on hiPSC that can predict developmental toxicity and that reflect key aspects of early embryonic development.

May 18, 2021 – New Approach Methods in genotoxicity and mechanistic toxicity testing for the animal-free safety assessment of novel pharmaceuticals and chemicals

Tuesday, May 18, 2021
10:00 – 11:00 EST / 16:00 – 17:00 CET

The recording is available here

Presented by: Giel Hendriks, CEO, Toxys

Every year, large numbers of new compounds are being developed for a wide range of purposes. Due to the large numbers of compounds that require safety assessment, there is an increasing demand for rapid and reliable in vitro assays that assess their toxicity in an early phase of drug or product development. At the same time, there is a strong demand to reduce animal testing. We have therefore developed various in vitro cell-based assays for chemical safety assessment with the focus on understanding the mode-of-action (MoA) of toxic compounds.

ToxTracker is a unique stem cell-based reporter assay for reliable genotoxicity and carcinogenicity hazard identification. The ToxTracker assay reliably identifies genotoxic compounds and provides insight into their mode-of-action. The assay is able to discriminate between direct DNA reactivity and indirect genotoxicity related to oxidative stress or protein damage and can differentiate between genotoxic compounds with a clastogenic or aneugenic MoA. Various extensions of ToxTracker to further investigate the MoA of genotoxic compounds are combined in the ToxTracker suite.

ToxProfiler is a human cell reporter assay that can accurately quantify the cellular stress responses that are induced by chemicals. The unique combination of seven fluorescent reporter cell lines for oxidative stress, genetic stress, ER stress, autophagy, ion stress, protein stress and inflammation and automated live-cell confocal microscopy are applied to generate a toxicological fingerprint and provide insight into the toxic MoA of compounds.

These unique animal-free in vitro assays provide reliable and accurate toxicity information that is relevant to human health. The assays are used for early compound screening, follow-up testing and MoA assessment, potency ranking and chemical read-across and are particularly useful in weight-of-evidence (WoE) and adverse outcome pathway (AOP) approaches for chemical safety assessment.

This image has an empty alt attribute; its file name is toxtracker-1.jpg

April 21, 2021 – Legal and Policy Considerations for the Use of New Approach Methodologies (NAMs) in Chemical Risk Assessment

April 21, 2021
10:00 – 11:00 EST / 16:00 – 17:00 CET

The recording is available here:

Gary Marchant, PhD, JD, Sandra Day O’Connor College of Law, Arizona State U.
Kirk T. Hartley, JD, ToxicoGenomica and LSP Group LLC

February 25, 2021 – Quantitative in vitro to in vivo extrapolation (QIVIVE)

Thursday, February 25th, 2021
10:00AM – 11:30AM EST

  • Presenters:
  • Martin Scholze, Centre for Pollution Research and Policy, Brunel University London, UK
  • Ans Punt, Wageningen Food Safety Research, The Netherlands

The recording is available here:


Martin Scholze, Centre for Pollution Research and Policy, Brunel University London, UK
Quantitative in Vitro to in Vivo Extrapolation (QIVIVE) for Predicting Reduced Anogenital Distance produced by Anti-Androgenic Pesticides in a Rodent Model for Male Reproductive Disorders

Many pesticides can antagonize the androgen receptor(AR) or inhibit androgen synthesis in vitro but their potential to cause reproductive toxicity related to disruption of androgen action during fetal life is difficult to predict. Currently, no approaches for using in vitro data to anticipate such in vivo effects exist, and prioritization schemes that limit unnecessary animal testing are urgently needed. Here I will present a quantitative in vitro to in vivo extrapolation (QIVIVE) approach for predicting in vivo anti-androgenicity arising from gestational exposures and manifesting as a shortened anogenital distance (AGD) in male rats. It is built on a physiologically based pharmacokinetic (PBK) model to simulate concentrations of chemicals in the fetus resulting from maternal dosing. The QIVIVE approach was evaluated by using several well-studied model compounds and then applied to various current-use pesticides, all with in vitro evidence for anti-androgenicity but missing in vivo data. Here the QIVIVE model newly identified fludioxonil, cyprodinil, and dimethomorph as in vivo anti-androgens. With the examples investigated, this approach shows great promise for predicting in vivo anti-androgenicity (i.e., AGD shortening) for chemicals with in vitro activity and for minimizing unnecessary animal testing.

Ans Punt, Wageningen Food Safety Research, The Netherlands
A web-based toolbox to support quantitative in vitro-to-in vivo extrapolations (QIVIVE)

An important aspect within next generation non-animal toxicity testing strategies is the extrapolation of in vitro effect concentrations into (human) dose−response or potency information, also called quantitative in vitro-to-in vivo extrapolation (QIVIVE). Insights in dose-dependent plasma and tissue concentrations of a chemical are required to infer the dose levels that would be needed to reach the in vitro effective concentrations in the body. Physiologically based kinetic (PBK) modelling plays a crucial role in generating such insights. To support PBK-model development we have developed a web-based toolbox ( that contains generic physiologically based-kinetic (PBK) models for rats and humans, including underlying calculation tools to predict plasma protein binding and tissue:plasma distribution. The PBK models within the toolbox allow to make first estimations of internal plasma and tissue concentrations of chemicals, based on the LogP and pKa of the chemical and values for intrinsic hepatic clearance and intestinal uptake. As case study, the toolbox was used to predict oral equivalent doses of in vitro ToxCast bioactivity data for the food additives methylparaben, propyl gallate, octyl gallate and dodecyl gallate. These oral equivalent doses were subsequently compared with human exposure estimates. The goal of the presentation is to provide a background on PBK model development and QIVIVE, making interactively use of the web-based toolbox.

January 14th, 2020 – ASCCT Award Winners Webinar: January 2021

Thursday, January 14 2021                                                                                                                                                     10:00-11:15  AM US ET// 4:00 PM – 5:15 PM CET

The recording is available here:


The Ed Carney Predictive Toxicology Award recognizes the first author of an outstanding poster or platform presentation that will advance predictive toxicology, and is named after Dr. Ed Carney, a member and supporter of the ASCCT and a leader in the predictive toxicology field. The 2020 winner was Eva C.M. Vitucci from University of North Carolina, Chapel Hill to for her presentation “Identifying the Molecular Mechanisms of Air Pollution-Induced Cardiovascular Disease”.

The Ray Tice Tox21 Student Award is presented to recognize the best student presentation during the meeting and was established with a generous donation from Dr. Ray Tice, a leader in implementing and setting the stage for Toxicity Testing in the 21st Century. The 2020 winner was Ms. Sherri Bloch from Université de Montréal for her presentation “Using in Vitro Data to Derive Acceptable Exposure Levels: A Case Study on PBDE Developmental Neurotoxicity”.


Using in vitro data to derive acceptable exposure levels: Case studies on PBDE
developmental neurotoxicity and DDE obesogenicity

Presented by: Sherri Bloch

Current acceptable exposure levels are mostly based on animal models, which are costly,
time-consuming, and may poorly predict adverse outcomes in humans. There is a need for
alternative testing methods that are faster, cheaper, and provide human-relevant information.
We aimed to evaluate a method using human in vitro data and biological modeling to calculate acceptable exposure levels through two case studies: One on PBDE developmental neurotoxicity and the other on p,p’-DDE obesogenicity due to early life exposure.
To accomplish our objectives, in vitro studies using human cells were compiled to select points of departure (POD) in the form of nominal medium concentrations. These were translated into cellular levels (target organ POD), and then converted into acceptable daily intakes and plasma concentrations in pregnant women using pharmacokinetic models of gestation/lactation and applying uncertainty factors. The final step of our methodology was the comparison of the derived chemical levels in maternal plasma to levels measured in epidemiological studies reporting associations between prenatal exposure and the adverse endpoints in children.
Estimated acceptable exposure levels and matching plasma levels showed concurrence with those measured in epidemiological studies, implying this approach may be viable. However, uncertainty factors need further investigation prior to application in risk assessment.

Identifying the Molecular Mechanisms of Air Pollution – Induced Cardiovascular Disease

Presented by: Eva Vitucci

An estimated 3.5-million people die annually from air pollution-induced cardiovascular disease (API-CVD). API-thrombosis (API-T) is a main contributor of these mortalities; however, the molecular mechanisms driving API-T are unclear. To identify these mechanisms we developed an in vitro model that represents the interface of the respiratory and cardiovascular system, the alveolar capillary region (ACR). This organotypic model includes human alveolar-like epithelial cells (H441), human lung fibroblasts, and human lung microvascular endothelial cells (HULEC). We hypothesized that air pollutant exposure of the H441 cells would initiate the onset of a pro-thrombotic state in the HULEC. To test this, we exposed H441 cells to the ubiquitous air pollutant, diesel exhaust particulates (DEP), and investigated the effect of this trans-alveolar exposure (TA-DEP) on the underlying HULEC. TA-DEP exposure induced expression of anti-oxidants such as heme oxygenase 1 and NAD(P)H dehydrogenase [quinone] 1, increased nuclear factor erythoid-2 related factor (NRF2) protein, and reduced glutathione redox potential in the HULEC. Concurrently, decreased expression of the endothelial fibrinolytic and anti-coagulant genes, tissue-type plasminogen activator, plasminogen activator urokinase, and thrombomodulin, and increased expression of the procoagulant gene, coagulation factor III occurred in the HULEC. These data suggest that TA-DEP exposure induces redox dysfunction and an endothelial pro-thrombotic profile in the ACR. We conclude that redox dysfunction and pro-thrombotic activation in the capillary beds of the ACR may be critical initiation steps of API-T. Data from this model can help develop intervention strategies against API-T and can encourage the development of organotypic models resulting in a reduction of animal testing. This does not reflect EPA policy.


Sheri Bloch – PhD Student – Université de Montréal

Sheri has a MSc in Pharmacology from the University of Montreal, in Quebec, Canada. She is currently doing a PhD in Toxicology and Risk Analysis, Department of Occupational and Environmental Health, School of Public Health at the University of Montreal. Sheri is also affiliated with the Center for Public Health Research in Montreal.

Eva Vitucci – PhD Student  – University of North Carolina, Chapel Hill

Eva has a B.S. in Microbiology from the University of Florida and is working on her PhD in the Curriculum in Toxicology and Environmental Medicine at the University of North Carolina – Chapel Hill.

Webinars – 2020

December 17th, 2020 – Medical Device Assessment: Updates for Thrombogenicity and Skin Irritation

Thursday, December 17th, 2020
11:00-12:30  AM US ET// 5:00 PM – 6:15 PM CET

In vitro methodology for medical device material thrombogenicity assessments

Presenter: Michael F. Wolf, PhD, Medtronic

In vivo vascular implant models are currently used to assess implant material thrombogenicity for medical devices. We report an in vitro thrombogenicity assessment methodology where test materials alongside positive and negative controls were exposed to fresh human blood, using gentle-agitation test tube and pulsatile-flow closed-loop models. We report that: thrombogenicity was strongly dependent on several experimental variables, and in vitro to in vivo case comparisons showed consistency in thrombogenicity rankings on a range of materials. In vitro methods using fresh human blood are scientifically sound and cost effective compared to in vivo methods for screening thrombogenicity.

In Vitro Irritation Testing for Medical Devices: A Progress Update

Presenter: Kelly P. Coleman, PhD, DABT, ERT, Medtronic

Assessment of skin irritation is an essential step in the biocompatibility evaluation of medical devices. Two international validation studies were conducted to evaluate reconstructed human epidermis (RhE) models as alternatives to the rabbit skin irritation test. First, extracts of four irritant polymers and three non-irritant controls were used with two types of RhE tissues. Both tissue types identified virtually all the irritant polymer samples, indicating that RhE tissue models can detect the presence of strong irritants at low levels in dilute medical device polymer extracts. The second study used two other types of RhE tissues and produced similar results. It was concluded that RhE models are suitable replacements for the rabbit skin irritation test to support the biocompatibility evaluation of medical devices, and in 2020 a new ISO 10993-23 standard was finalized which states that the use of RhE tissues is preferable to rabbits.

Register here:

November 30th, 2020 – Development of a Bayesian Network Model for Predicting Fish Acute Toxicity from Fish Embryo Toxicity Data

Monday, November 30 th, 2020
10:00-11:00  AM US ET// 16:00-17:00 CET

Presenter: Adam Lillicrap, Norwegian Institute for Water Research 

Reduction of animal testing, wherever possible, is required by legislations such as the EU Directive 2010/63/EU. Fish Embryo Toxicity (FET- OECD TG236) testing has been proposed to be an alternative to the juvenile acute fish toxicity test (AFT- OECD 203). However, FET data are not yet accepted as a replacement to the AFT test for certain regulatory purposes such as REACH. The European Chemicals Agency (ECHA) recommended that a weight-of-evidence (WoE) approach was needed for FET data before it could possibly be used in place of AFT data. Therefore, a Bayesian network (BN) model has been developed to incorporate multiple lines of evidence, in combination with FET data, to predict AFT. Bayesian networks are increasingly being used in ecological risk assessment because they can integrate large amounts of data and other information sources to produce discrete probability distributions, and predict the probability of specified states.


The objectives of this study were:

1) To develop and evaluate a BN model for predicting toxicity of substances to juvenile fish from embryo toxicity data in combination with other relevant information;

2) To apply the BN model in a WoE approach which can support replacing juvenile fish toxicity testing with embryo toxicity testing.

The BN model correctly predicted the AFT toxicity level for 14 substances, and gave lower toxicity for 6 substances. For the 6 substances with an incorrect prediction, 5 substances (2,4-Dichlorophenol, 4-Chlorophenol, Malathion, Naphthalene, Prochloraz) were less toxic to fish than to daphnids or algae, hence the AFT data would not drive the environmental risk assessment for those substances. In the case of 1 of the substances (Juglone), the AFT test was less sensitive than the FET data.

Register here:

September 24, 2020 – Phenotypic profiling for high-throughput chemical screening at the U.S. EPA

September 24th, 2020
10:00-11:00  AM US ET// 16:00-17:00 CET

Presenter: Johanna Nyffeler, ORISE Fellow with US EPA

The Center for Computational Toxicology & Exposure (CCTE) at U.S. EPA developed a blueprint for utilization of new approach methodologies (NAMs) in computational toxicology. The tiered approach relies on high-throughput profiling assays in the first step in characterizing the biological activity of chemicals. Chemicals are run in concentration-response in the assays for two purposes: (1) To derive a potency estimate for chemical bioactivity. This in vitro potency estimate can then be used to prioritize chemicals and/or compare the bioactivity to exposure estimates. (2) To gain information about putative mechanisms-of-actions. Depending on the mechanisms-of-action, different second and third-tier assays may then be performed to confirm hypothesized bioactivity. CCTE currently has two such profiling assays: High-throughput transcriptomics and imaging-based high-throughput phenotypic profiling (HTPP). In the webinar, I will outline our efforts to achieve these two purposes for HTPP assay. For HTPP, we are using an assay called ‘Cell Painting’, that labels multiple cellular organelles (nucleus, nucleoli, endoplasmic reticulum, golgi, actin skeleton, plasma membrane, mitochondria) to measure changes in cell morphology in response to chemical treatment. We have operationalized the assay for 384 well plates to run concentration-response screenings and extract 1300 features on a single-cell level. To date we have screened > 1200 chemicals at 8 concentrations in human U-2 OS sarcoma cells. We have derived potency estimates (i.e. phenotype altering concentrations, PACs) for all active chemicals. For 303 chemicals, in vitro-to-in vivo extrapolation was performed to compare the potency estimates to available in vivo data. For 78% of the chemicals, the HTPP potency was within two orders of magnitude from the in vivo point-of-departure. Moreover, for 72% of chemicals, HTPP was comparable or more conservative than the in vivo point-of-departure. For each active chemical, a phenotypic profile was derived from the 1300 measured features. Profiles were then compared using Pearson correlation. Among the tested chemicals were 179 chemicals with target annotations in the RefChemDB database. We could show that for two pathways (retinoic acid pathway, glucocorticoid receptor), chemicals activating the same target also display high profile similarity. Moreover, by comparing all tested chemicals to the annotated chemicals, we identified five test chemicals with high profile similarity to retinoids. Of those, four were not previously identified as modulators of the retinoic acid pathway. To summarize, our results to date indicate that the HTPP assay can be used to derive potency estimates as well as some mechanistic information that can both be used for prioritization of chemicals. This abstract does not reflect U.S. EPA policy.


August 20, 2020 – PubMed Abstract Sifter: a literature informatics tool for chemical research

Thursday, August 20th, 2020
10:00-11:00  AM US ET// 16:00-17:00 CET

Presenter: Nancy C. Baker, Leidos, Inc. and US EPA

Assessing and understanding chemical effects requires assembling information from a wide variety of sources, including millions of articles in the biomedical literature. Literature informatics approaches can help researchers make use of this information in more effective ways. We present the PubMed Abstract Sifter, a freely available literature tool from the US Environmental Protection Agency. With the Abstract Sifter, researchers can easily retrieve and triage citations from PubMed and visualize the literature landscape for a set of chemicals. The tool is supplied with template queries that facilitate the exploration of mechanistic information by using the language of Adverse Outcome Pathways (AOPs) and Key Characteristics of Carcinogens. 

This abstract does not necessarily represent US EPA policy.  

Registration is now open:

July 8, 2020 – Human biology-based approaches for COVID 19 therapeutics

Wednesday, July 8, 2020
11:00-12:30 EDT / 17:00-18:30 CET

First speaker: Malcolm Wilkinson, Kirkstall
Title: Building more physiological models of human disease 
Quasi Vivo® Systems are a way to introduce air and media flow over in vitro cell cultures and can be used to create multi-cell or multi-organoid models for the study of disease. Current projects specifically focused on  COVID-19 include: 1) development of a model that mimics infection of by SARS-CoV-2 with natural flow of lymph and blood in the body and assess responses to the entry of SARS-CoV-2 in cells from the respiratory tract and responses on circulating blood cells from the immune system, 2) building a multi-tissue model which replicates human obesity and how different tissues communicate with each other in diseases like SARS-COVID19, and 3) improving our understanding of how cigarette smoke increases susceptibility to SARS-CoV-2 infection in the lungs and help in developing a therapy for prevention and treatment.

Second speaker: Samuel Constant, Epithelix
Title: 3D Human epithelial models to study SARS-CoV-2 pathogenesis
The respiratory system is the main entry portal of SARS-CoV-2 which infects initially and principally the airway epithelia. Epithelix has developed standardized air-liquid interface 3D human airway epithelial cultures from nasal or bronchial (MucilAir™) and small-airway (SmallAir™) origins. These epithelial models closely mimic the morphology and function of the native tissues and have been used for the development of antivirals against influenza, rhinoviruses, respiratory syncytial virus, amongst others. This talk will highlight how these reconstituted human airway epithelial models can be used to characterize viral infection kinetics, tissue-level tropism and transcriptional immune signatures induced by SARS-CoV-2. Relevance of these models for the preclinical evaluation of antiviral candidates will also be addressed in the context of repositioning of marketed drugs or evaluation of novel therapies and combinations delivered systematically or through aerosol therapy.

Registration link:

June 9, 2020 – The Use of Machine Learning and Artificial Intelligence in Toxicology and Risk Assessment

Tuesday, June 9, 2020
10:00 AM US ET / 16:00 CET

Presenter: Timothy E H Allen, Research Scientist, Willis Group, MRC Tox

Artificial intelligence (AI) and machine learning (ML) algorithms are gaining a lot of attention in toxicology. These algorithms are advantageous as they can identify new patterns in data and make predictions in a way and on a scale that human scientists cannot. What are they and how do they work? How do they learn and help make decisions? And where do they fit into the science of toxicology? Some of these questions and some of the myths surrounding these research areas will be addressed in this talk. This will include introducing some of the ideas in AI and ML and explaining how some algorithms, including random forests and neural networks, work. This will be followed with a focus on the areas of toxicology in which we are trying to apply these ideas – specifically in the area of predictive toxicology. Computational models have been constructed based on structural alerts, random forests and neural networks to predict pharmacologically important human molecular initiating events, the initial interactions molecules make with biomolecules or biosystems that can lead to adverse outcomes. Attempts are also being made to overcome the disadvantages of these algorithms – particularly how they are seen as “black boxes” with little understanding of their internal working – by combining their predictions and comparing how different chemicals are assessed by the algorithms. AI and ML approaches undoubtedly have a major role to play in the future of toxicology – but a greater understanding of the algorithms, how they work and why specific predictions are made are areas that need to be considered to see greater adoption of these valuable tools. Approaches such as those presented here allow us to answer some of these questions and can support the use of their powerful predictivity in safety science.

Register Now:

May 26, 2020 – International computational collaborations for predictive toxicology

Tuesday, May 26, 2020
11:00 AM US ET / 17:00 CET

Presenter: Kamel Mansouri, Integrated Laboratory Systems, Inc.

Humans are exposed to an ever-increasing number of chemicals, but only a fraction of these have been evaluated for potential risks to human health and the environment. Thus, both regulators and manufacturers need rapid and efficient approaches to evaluate the potential toxicity of thousands of chemicals already in commerce and others in development. Advances in information technology and machine learning have fostered the development of in silico approaches that leverage the relationships between chemical structures and their biological activities. However, individual predictive computational tools are associated with certain limitations, and they are only as good as the input data upon which they are built. To address these challenges, international consortia involving over 100 scientists from governmental agencies, academia, and industry were formed to collaboratively develop in silico tools for predicting chemical toxicity. These consortia have successfully concluded three projects: the Collaborative Estrogen Receptor Activity Prediction Project (CERAPP), the Collaborative Modeling Project for Androgen Receptor Activity (CoMPARA), and the Collaborative Acute Toxicity Modeling Suite (CATMoS). These projects used data from both the published literature and the ToxCast/Tox21 programs curated to meet defined quality specifications. Limitations of individual modeling approaches were overcome by establishing consensus models that leveraged each model’s strengths. The resulting consensus models have been used to screen hundreds of thousands of chemicals from the U.S. Environmental Protection Agency’s (EPA’s) DSSTox database. These models are freely available for further use through the OPEn structure-activity/property Relationship Application (OPERA), as an open-source standalone application and by querying the EPA’s CompTox chemistry Dashboard ( and NTP’s Integrated Chemical Environment (

Register Now:


[1] Mansouri, K. et al. EHP:

[2] Mansouri K. et al. J Cheminform:

[3] Kleinstruer N.C. et al. Comput Toxicol:

[4] Mansouri, K. et al. EHP:

April 30, 2020 – Use of New Approach Methodologies for cosmetic safety assessment without animal testing

Thursday, Apr 30, 2020
11:00 AM US ET / 17:00 CET

Recent advances in chemical safety assessment now allow the complete evaluation of personal care products without the use of animals. Exposure based approaches and hypothesis-driven data generation form the basis of non-animal cosmetic safety assessments.  The safety assessment approach begins with problem formulation and evaluation of existing information before considering the development of targeted testing approaches. Assessment tools, often described as New Approach Methodologies (NAMs), can include computational models and human-relevant in vitro assays which are applied in combination to provide information on ingredient hazard and risk assessment. Finally, these disparate types of information are integrated and weighted in a transparent assessment that captures uncertainty. Each presentation in this webinar will cover different aspects of this decision process.

Register Now


11:00 Introduction: Hypothesis led safety assessment of cosmetics,
Catherine Willett, Humane Society International

11:10  Exposure based safety assessment of cosmetics,
Corie Ellison, Procter and Gamble

11:25  The application of in silico models to support decision making in toxicology: QSAR, informatics, pathway modelling, uncertainty,
Chris Barber, Lhasa, LTD

11:40 In vitro approaches to cosmetic safety assessment
Paul Walker, Cyprotex Discovery Ltd

11:55 Integration of new approach methodologies for cosmetic safety decision making
Matt Dent, Unilever

11:10 Q & A
For more information about the project, see

March 11th, 2020 – ASCCT Award Winners Webinar – Toxicological mechanistic inference: Generating mechanistic explanations of adverse outcomes

Wednesday, March 11th, 2020
11:00 AM US ET / 17:00 CET

Presenter: Ignacio J. Tripodi, PhD Candidate in Computer Science / Interdisciplinary Quantitative Biology, University of Colorado, Boulder
Registration Link:

Government regulators and others concerned about toxic chemicals in the environment hold that a mechanistic, causal explanation of a mechanism of toxicity is strongly preferred over a statistical or machine learning-based prediction by itself. We thus present a mechanistic inference framework, which can generate hypotheses of the most likely mechanisms of toxicity for a specific chemical and cell type, using gene expression time series on human tissue and a semantically-interconnected knowledge graph. We seek enrichment in our manually-curated list of high-level mechanisms of toxicity (e.g. “Triggering of caspase-mediated apoptosis via release of cytochrome C”, or “Mitochondria-mediated toxicity by inhibition of electron transport chain”), represented as causally-linked Gene Ontology concepts.

Our knowledge representation is an extension of the PheKnowLator knowledge graph. It consists of an integration of concepts from multiple ontologies (GO, PRO, HPO, ChEBI, PATO, DOID, CL), as well as relevant concepts from Reactome, Uniprot, the cellular toxicogenomics database (CTD), and the AOP Wiki. The expression assays were obtained from the Open TG-Gates, CarcinoGenomics, and other projects, consisting of human liver, kidney, and lung, bronchial, buccal, and nasal epithelial cells exposed to a sizeable number of chemicals that elicit different mechanisms of toxicity. Both our knowledge graph and experimental transcriptomics data are human-centric. Besides predicting the most likely mechanisms of toxicity from the transcriptomics assays, we generate putative explanations based on the most significant genes at each time point with known links to their corresponding mechanism steps. This provides a transparent, possible explanation for the mechanisms of toxicity, that would help a researcher’s decision-making process and aid further experimental design. Furthermore, we were able to experimentally validate our mechanistic predictions for some chemicals without an established mechanism of toxicity.

Co-expression Network Analysis to Identify Heterogeneity Between the Breast Cancer Cell Line MCF-7 and Human Breast Cancer Tissues

February 25th, 2020 – Moving away from animal testing for acute inhalation toxicity testing

Tuesday, February 25th, 2020
10:00 AM US ET / 17:00 CET

Presented by Emilie Da Silva, PhD student, Technical University of Denmark/National Research Center for the Working Environment, Denmark
Registration Link:

ABSTRACT: Testing for acute inhalation toxicity is required for chemicals manufactured or imported at tonnages ≥ 10 tons per year (Commission Regulation (EC) No 440/2008) and for biocides (Regulation (EU) No 528/2012) and plant protection products (Regulation (EU) No 283/2013) before they are allowed on the market. Currently, three OECD Test Guidelines are available (TG 403, TG 436, and TG 433), all based on the exposure of rodents to the substance of interest for up to 4 hours. The use of animals for toxicological evaluation does not come without challenges. Animal experiments are costly and time consuming. It is estimated that the turnaround time for carrying out an acute inhalation test is 3 to 4 months. Besides, using rodents in order to predict the toxicity of a compound in humans is arguable given the differences in the features of the respiratory tract. The development and the validation of alternative methods in chemico, in vitro and/or in silico are needed. To do so, the mechanistic understanding of the toxicity of inhaled chemicals is key.

An innovative in vitro method for acute inhalation toxicity will be presented. This cell-free method is based on the monitoring of lung surfactant function. Indeed, the lung surfactant layer in the alveoli is the first barrier that inhaled compounds will encounter when they reach the respiratory region in the lungs. The correlation between the inhibition of the lung surfactant function and the decrease in tidal volume in mice was shown with a variety of compounds including excipients for drug formulation, and impregnation spray products. During this webinar, the method will be introduced and explained, and case studies using different chemical groups will be presented.

January 21, 2020 – ESTIV Award Winners Webinar – Role of In Vitro Mechanistic Data for the Assessment of Endocrine Disruptors in the Regulatory Context

Presented by Dr. Laura Escrivá, Assistant Professor, University of Valencia, Spain.
Tuesday, January 21st, 2020 at 4:00 pm CET

Available online at:

ABSTRACT: Scientific EU criteria and guidance from ECHA and EFSA to identify substances with Endocrine Disruptor (ED) properties have recently been implemented for plant protection products and biocidal products. The ECHA/EFSA guidance, mainly addressing EATS (estrogen, androgen, thyroid, steridogenesis) modalities, provides a protocol for ED identification, which includes the evaluation of both the adverse effects and the endocrine activity, by applying weight of evidence analysis.

The assessment of the endocrine activity requires in vitro mechanistic data providing information on the mechanism through which a substance could be considered endocrine active (e.g. by binding to and activating a receptor or interfering with hormone production). Moreover, when potentially endocrine-related adverse effects and endocrine activity are identified, the biological plausibility of the link between endocrine activity and the endocrine mediated adversity should be established by a mode of action analysis. The webinar will focus on the different steps for ED identification according to the ECHA/EFSA guidance illustrating how essential it is the in vitro data for ED assessment under EU regulatory context.

January 21, 2020 – ESTIV Award Winners Webinar – A battery of animal-free in vitro assays for evaluating prenatal developmental toxicity potency of highly complex petroleum substances

Presented by Dr. Lenny Kamelia, Division of Toxicology, Wageningen University and Research, The Netherlands.
Tuesday, January 21st, 2020 at 4:00 pm CET

Available online at

ABSTRACT: REACH legislation requires prenatal developmental toxicity (PDT) testing for substances registered at a volume of >100 tonnes/year, which also applies to petroleum substances (PS). Given that i) PDT testing is one of the most complex, and animal- and resource-intensive regulatory requirements for substances produced at >100 tonnes/year, and ii) PS are highly complex materials (UVCBs), the development of alternative non-animal based testing strategies for PS poses huge challenges. Some PS contain high concentrations of polycyclic aromatic hydrocarbons (PAHs) and we hypothesize that PDT as observed for some PS is caused by certain types of PAH present in these products. To this purpose, DMSO-extracts of 9 PS (varying in PAH content; from 5 different product categories), 1 highly refined base oil (HRBO) (containing no PAHs), and 2 gas-to-liquid (GTL) products (devoid of PAHs) were tested in a battery of in vitro assays, including the embryonic stem cell test (EST), the zebrafish embryotoxicity test (ZET), and the aryl hydrocarbon (AhR) CALUX assay. All DMSO-extracts of the PS, but not of the HRBO and GTL, induced concentration-dependent PDT as quantified in the EST and ZET, with their potency being proportional to their 3- to 7-ring PAH content. Moreover, all PS extracts also showed AhR-mediated activity in the AhR CALUX assay, suggesting a role of the AhR in mediating the observed PDT by these substances. Combining the results of the EST, ZET, AhR CALUX assay, and the PAH content, ranked and clustered the test compounds in line with their in vivo PDT potencies. In conclusion, our battery of in vitro assays, consisting of the EST, ZET and AhR CALUX assay, is able to evaluate and differentiate the PDT potency of highly complex PS, within and among categories. The results are also in concordance with our hypothesis on the role of specific groups of PAHs present in some PS for the observed PDT induced by these substances.

Archived Webinars – 2019

Archived videos of past webinars are available to ASCCT membersContact the ASCCT Secretary for more information or to suggest a topic for a future webinar.

Deep Learning in Toxicity Prediction: Reasons for Use and Possible Applications

Presented by Dr. Suman Chakravarti, Chief Scientific Officer, MultiCASE
December 4, 2019 at 4:00 pm CET

ABSTRACT: Use of deep learning is increasing in solving different problems in computational toxicology and QSAR methodology in general. However, it is important to recognize the strengths of deep learning techniques in order to get the best out of them.
This webinar will focus on different aspects of computational toxicity assessments that can be improved using deep learning techniques beyond just increasing the accuracy of the predictions. For example, building scalable QSARs using big data, eliminating the use of precomputed descriptors from QSARs, expanding domain of applicability of QSARs and identification of toxicity alerts using deep learning techniques. In addition, available free tools and different types of deep learning architectures that are relevant to toxicity assessments will be discussed with the aid of case studies.

December 4th Webinar, Deep Learning in Toxicity Prediction: Reasons for Use and Possible Applications, presented by Suman Chakravarti, Chief Scientific Officer, MultiCASE, has been posted online and is now available for viewing at your convenience.

The pros and cons of 3D in vitro cultures of liver fibrosis

Presented by Leo van Grunsven, Vrije Universiteit Brussel.
November 4, 2019 at 4:00 pm CET

ABSTRACT: Chronic liver disease is the major cause of progressive liver fibrosis which, in turn, leads to cirrhosis of the liver. One major obstacle in the development of efficient therapies is the lack of robust and representative in vitro models of human liver fibrosis to aid in understanding the basic mechanisms of the disease and in the development phase of pharmaceuticals. The aim of this presentation is to give some background on the mechanisms involved in liver fibrosis development and why our work is based on the central hypothesis that liver fibrosis in vitro cannot be studied using only hepatic stellate cells (HSCs)–the main producer of scar tissue during fibrosis. I will present and discuss some results and problems we faced while developing an in vitro liver fibrosis model. We established a model in which HepaRG cells (Biopredic) were co-cultured with either in-house isolated HSCs or in-house differentiated induced pluripotent stem cell derived HSCs. In both cases, exposure to hepatotoxins resulted in hepatocytic damage and consequent HSC activation. We now work on a model using only primary mouse HSCs and hepatocytes. I will also discuss some of our work aiming at developing more complex primary mouse co-cultures for liver disease modeling and briefly address the work of other groups that reported on such complex in vitro culture systems.

The November 4th Webinar, The pros and cons of 3D in vitro culture models of liver fibrosis, presented Prof. Leo A. van Grunsven, Vrije Universiteit Brussel, has been posted online and is now available for viewing at your convenience.

Translational challenges in in vitro nephrotoxicity model

Presented by Roos Masereeuw, Div. Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands.
October 22, 2019 at 4:00 pm CET

ABSTRACT: Adverse effects caused by exposure to foreign compounds, including drugs, often involve the kidney. In fact, 14 to 26% of the acute kidney injury events reported can be related to drug-induced kidney injury. Although acute damage to the kidney may be reversible, depending on severity, 30% of the patients develop structural renal dysfunction leading to chronic kidney disease eventually progressing into end-stage kidney disease. Early prediction of adverse effects such as drug interactions and renal toxicity is therefore imperative for clinical practice and for the development of new and safe drugs. Current in vitro assays do not accurately allow such prediction, predominantly due to inadequate preservation of the organs’ microenvironment. The kidney epithelium is highly polarized, and the maintenance of this polarity is critical for optimal functioning and responsiveness to environmental signals influencing cell proliferation, migration and differentiation. This presentation will provide an overview of advances in 3D cultures of human renal cells and organoids in microfluidics, and in particular kidney tubules, thereby improving physiological performance of the tissue. These microphysiological systems have great potential for drug screenings and provide novel alternative strategies for the prediction of renal drug disposition and safety assessment in a human-specific context. However, knowledge gaps in quantitative translation of renal drug disposition from microphysiological systems still exist and will be discussed.

Developmental neurotoxicity evaluation: on the road to regulatory acceptance

Presented by Prof. Ellen Fritsche, Leibniz Research Institute for Environmental Medicine-Germany

August 28, 2019 at 4:00 PM CET

Nerve-on-a-chip platform for assessing chemotherapy-induced peripheral neuropathy

Presented by Dr. Lowry Curley, AxoSim Inc.
September 17, 2019 at 5:00 PM CET:

Using Quantitative Systems Toxicology (QST): Improving the safety of drugs while reducing animal testing (July 2019) Presenter: Paul B. Watkins, M.D., University of North Carolina – Chapel Hill

GARD™air – An in vitro assay to test for respiratory sensitizers using genomic biomarkers and machine learning (June 2019) Presenter: Joshua Schmidt, SenzaGen Inc., USA Co-author: Andy Forreryd, SenzaGen AB, Lund, Sweden

EPA computational tools (May 2019)
The CompTox Chemicals Dashboard and Generalized Read Across
Presenters: Antony Williams and Grace Patlewicz, EPA

Automated and Integrated Analysis Workflow for Adverse Outcome Pathway Identification, Hypothesis Generation and Risk Assessment (April 2019) Presenters:
Noffisat O. Oki (1) and Tatyana Doktorova (2)
1Edelweiss Connect Inc, Durham, NC, USA
2Edelweiss Connect Gmbh, Basel, Switzerland

Advancing tools for predictive toxicology (March 2019) Title: Establishment of bile duct tubular structure mimicking the intrahepatic bile duct morphogenesis for an in vitro bile recovery
Presenters: Astia Rizki-­‐Safitri, Marie Shinohara, Minoru Tanaka, and Yasuyuki Sakai

Title: Generation of recombinant human anti-diphtheria toxin neutralizing antibody to replace equine sera
Presenters: Esther Wenzel, Paul Stickings, Jeffrey Brown, Thea Sesardic, Androulla Efstratiou, Michael Hust

Title: Development and Use of Adverse Outcome Pathway (AOP) Networks to Support Assessment of Organ Level Effects
Presenters: Nicoleta Spinu, Mark TD Cronin, Steven J. Enoch, and Judith C Madden

Combining biological and computational approaches (February 2019) Presenter 1: Daniel Russo, Rutgers University
Title: Developing Mechanism-Based Animal Toxicity Models: A Chemocentric Approach Using Big Data

Presenter 2: Sudin Bhattacharya, Michigan State University
Title: Integrating Genomics and Epigenomics into Predictive Toxicology of the AH Receptor

Nanoceramic pulmonary toxicity & reproducible cell line technology (January 2019)

Award Winners Series: Nanoceramic pulmonary toxicity & reproducible cell line technology
Jan 23, 2019 10:00 AM EST

Presenter 1: Maria João Bessa, PhD candidate, Portuguese National Institute of Health
Title: Pairwise toxicity evaluation of ceramic nanoparticles exposure in human alveolar epithelial A549 cells at submerged and air-liquid cultures

Presenter 2: Tom Wahlicht, PhD, InSCREENeX GmbH
Title: Reproducible in vitro toxicology testing using functional immortalized cells